Abstract
Vitreoretinal lymphomas are rare ocular cancers, and the subset of primary central nervous system lymphomas that are based in the posterior eye. These tumours are challenging to treat, and today management generally involves a multispecialty team coordinating a treatment protocol that may include intraocular chemotherapy, ocular irradiation, systemic chemotherapy and/or autologous stem cell transplantation. The ophthalmologist has specific responsibility for the intraocular chemotherapy, which is delivered to the eye by intravitreal injection. The most commonly injected drugs are methotrexate—an anti‐metabolite—and rituximab—an anti‐human B cell monoclonal antibody. A range of intraocular chemotherapy treatment schedules have been described in the medical literature, although to date there have been no randomized clinical trials of these schedules. In this article, we review the development and current status of intraocular chemotherapy for vitreoretinal lymphoma.
| Original language | English |
|---|---|
| Pages (from-to) | 240-248 |
| Number of pages | 9 |
| Journal | Clinical and Experimental Ophthlamology |
| Volume | 48 |
| Issue number | 2 |
| Early online date | 3 Nov 2019 |
| DOIs | |
| Publication status | Published - 1 Mar 2020 |
Keywords
- drug therapy
- eye
- vitreoretinal lymphoma
- retina
- intraocular chemotherapy
- lymphoma
